Antibodies

13 Jul 2021 Janssen Announces U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
12 Jul 2021 Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
11 Jul 2021 Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
11 Jul 2021 U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
09 Jul 2021 Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
09 Jul 2021 ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
09 Jul 2021 Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study
09 Jul 2021 FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
09 Jul 2021 DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU(R) Initiated in Patients with HER2 Positive Advanced Gastric Cancer
08 Jul 2021 Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma
07 Jul 2021 NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
07 Jul 2021 NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors
07 Jul 2021 EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06
07 Jul 2021 Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
07 Jul 2021 Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA
06 Jul 2021 Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
06 Jul 2021 Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
06 Jul 2021 Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002
06 Jul 2021 Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)
06 Jul 2021 FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
04 Jul 2021 ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
04 Jul 2021 Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
04 Jul 2021 Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
03 Jul 2021 GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
02 Jul 2021 Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top